Detalle Publicación

BEATcc (ENGOT-Cx10/GEICO 68-C/GPG3030/JGOG1084): A randomized, open label, phase III study of cisplatin and paclitaxel chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m/r) carcinoma of the cervix (CCx).

Autores: Oaknin, A.; Gladieff, L. ; Colombo, N. ; Villacampa, G.; Mirza, M. R.; De Giorgi, U. ; Randall, L. M. ; Takekuma, M.; González Martín, Antonio

Título de la revista: JOURNAL OF CLINICAL ONCOLOGY

ISSN: 0732-183X

Volumen: 37

Número: 15

Fecha de publicación: 2019

DOI: https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS5594

Impacto:

Google Scholar

Menú de navegación

Detalle Publicación

BEATcc (ENGOT-Cx10/GEICO 68-C/GPG3030/JGOG1084): A randomized, open label, phase III study of cisplatin and paclitaxel chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m/r) carcinoma of the cervix (CCx).